Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. Etoricoxib is a potent, orally active & highly selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 is primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Etoricoxib decreases these clinical signs and symptoms effectively with decreased GI toxicity. Moreover it has no effect on platelet function.
Etoricoxib is indicated for relief of pain and inflammation in-
- Rheumatoid arthritis
- Other chronic musculoskeletal disorders
- Acute gout
- Following dental surgery
The recommended dose for adult and patient over 16 years:
- Acute pain: 120 mg once daily. Etoricoxib 120 mg should be used only for acute symptomatic period, limited to a maximum of 8 days treatment.
- Chronic musculoskeletal pain: 60 mg once daily.
- Osteoarthritis: 30 mg once daily, increased if necessary to 60 mg once daily.
- Rheumatoid arthritis and ankylosing spondylitis: 90 mg once daily.
- Acute gout: 120 mg once daily for max. 8 days. Max. 60 mg daily in mild hepatic impairment; max. 60 mg on alternate days or 30 mg once daily in moderate hepatic impairment.
Dry mouth, taste disturbance, mouth ulcer, flatulence, constipation, appetite and weight changes, chest pain , fatigue, paraesthesia, influenza like syndrome, myalgia etc. may occur.
A patient with decreased liver & kidney function, dehydration, hypertension, heart failure, GI perforation & patients over 65 years of age. Use in Pregnancy and Lactation As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known whether this drug is excreted in human milk.
Oral anticoagulants, diuretics and ACE inhibitors, Acetylsalicylic acid, Cyclosporin and Tacrolimus, Lithium, Methotrexate, oral contraceptives, Prednisone/Prednisolone, Digoxin, drugs metabolized by sulfotransferases (Ethinyl Estradiol), drugs metabolized by CYP isoenzymes, Ketoconazole, Rifampicin, and Antacids have interaction with Etoricoxib.
Pregnancy Lactation use
As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only ifthe potential benefit justifies the potential risk to the foetus. It is not known whether this drug is excreted in human milk.
It is contraindicated in patients with hypersensitivity to Etoricoxib or any component of this product, congestive heart failure, patients with inflammatory bowel disease, severe hepatic dysfunction.
Symptoms: GI and cardiorenal events.
Management: Symptomatic and supportive treatment. Remove unabsorbed material from the GI tract.
Interaction with other Medicine
Store at a cool & dry place protected from light & moisture. Keep out of reach of children.